The Bull Rankings scorecard — our quality-growth score is 63.3 / 100, built from three pillars scored 0–100: Quality 47, Growth 85, Value 64 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 58% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Corcept’s current price of $111.8 sits on a $12.1 b market cap that already prices in a 58 %/yr free‑cash‑flow growth (in year one, slowing to 3% a year by year ten), per our reverse‑DCF. That projection dwarfs the 16 % revenue growth YoY reported for FY 2026, implying the market is betting on a dramatic acceleration in the coming years. The Bull Rankings model gives CORT a 63.3/100 quality‑growth score, with Growth 85 eclipsing Quality 47 and Value 64. The growth pillar is the engine of the thesis; the weak quality pillar signals that the company’s current operational metrics are still maturing. If the company can lift its free‑cash‑flow trajectory to match the implied 58 % growth, the stock is already priced for a high‑growth scenario. The thesis, therefore, hinges on whether CORT can deliver cash‑flow growth anywhere near 58 %, leveraging its unique product pipeline to capture a sizable niche in endocrinology.
What the business actually is
Corcept’s revenue engine is anchored by Korlym, an oral drug for hyperglycemia secondary to hypercortisolism in adults with Cushing’s syndrome who are either post‑surgery or ineligible for surgery. The drug targets a very specific patient group—those with type 2 diabetes mellitus or glucose intolerance—making it a niche but high‑value therapy. In addition, Corcept is developing relacorilant, a selective cortisol modulator for hypercortisolism, and miricorilant, a Phase 1b candidate for metabolic dysfunction. These assets collectively serve the endocrinologic, metabolic, and neurologic segments, with Korlym currently the only marketed product.
Why it can (or can't) keep compounding
The moat is built on regulatory exclusivity and a high‑bar entry for competitors. Korlym’s indication is highly specialized, and new entrants face a long development and approval cycle. Margins remain modest at 6.6 %, but the company’s debt‑to‑equity of 0.01 and free‑cash‑flow of $107 m indicate a lean balance sheet that can fund incremental R&D without borrowing, though the model’s “Diluting shareholders” signal shows the share count has been creeping up anyway. The beta of 0.45 shows limited volatility, suggesting the stock is not wildly sensitive to market swings. If the relacorilant and miricorilant programs reach commercialization, the revenue base could expand beyond the current niche, reinforcing compounding growth.
The valuation question
At $111.8 the price implies a P/S of 14.5. Our reverse‑DCF suggests a 58 %/yr FCF growth, far above the 16 % revenue growth reported. This gap indicates that the market is already pricing in a sharp uptick in profitability—perhaps from the upcoming launch of relacorilant or miricorilant. If the company fails to accelerate FCF, the valuation would be overextended. Conversely, if the pipeline delivers, the implied growth is realistic and the stock would be a bargain relative to the projected cash flows. The analyst consensus 1‑year target of $141 reflects a modest upside, but the reverse DCF suggests the current price is only fair if the 58 % FCF trajectory is achieved.
The bear case
The strongest skeptic points to the weak quality pillar (47). Corcept’s operating metrics—profit margin 6.6 % and ROE 7.8 %—are modest compared to peers, and even the PEG ratio of 0.81 depends on earnings growth that hasn’t arrived yet. If the relacorilant program stalls or faces regulatory setbacks, the company could revert to a low‑margin, high‑cost model, eroding the implied 58 % FCF growth. The “Diluting shareholders” signal further warns that future equity issuances could dilute existing equity, compressing per‑share earnings and free cash flow.
What would change our mind
- FCF growth falling below 30 % for two consecutive quarters would invalidate the 58 % implied growth assumption.
- Profit margin slipping below 5 % would signal deteriorating cost control, weakening the quality pillar.
- Relacorilant failing to win approval, or miricorilant stalling in development, would remove the primary growth catalyst, turning the thesis into a speculative bet on a single niche drug.
If any of these thresholds are breached, the thesis would shift from a growth‑oriented play to a high‑risk speculative position.